{
  "pmcid": "12353487",
  "sha256": "4677b5418ddf6ba386d6c8ff1208e4c70c59a938da583d36f4372da61d30c0cf",
  "timestamp_utc": "2025-11-09T22:22:43.500077+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.052078619909505,
    "reading_ease": 11.748344174208171,
    "word_count": 221
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Perioperative Normoxia vs. Hyperoxia in Cyanotic Neonates Undergoing Cardiopulmonary Bypass"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 29 neonates with cyanotic congenital heart disease were enrolled at a single tertiary care center."
      },
      "Participants": {
        "score": 2,
        "evidence": "29 neonates with cyanotic congenital heart disease were enrolled at a single tertiary care center."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to either normoxia (PaO2 60–100 mmHg) or hyperoxia (PaO2 200–300 mmHg) during cardiopulmonary bypass."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the feasibility, safety, and oxidative stress response of perioperative normoxia versus hyperoxia in cyanotic neonates undergoing cardiopulmonary bypass."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was serum thiobarbituric acid reactive substances (TBARS) measured at baseline, 2, 6, and 24 hours postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Fifteen neonates were randomised to normoxia and 14 to hyperoxia."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "TBARS levels were significantly lower in the normoxia group at all time points (p<0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No severe adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}